Hopefully, Indaflex will be a hit in China next year and they can use those revenues to run the clinical trials on zysolin and vansolin. Once they have a decent body of data, then they can partner up and get these drugs to market as quickly as possible.
Anyone know how Indaflex sales in China are going to work? With Mexico, I think we get 5% from Andromaco.